Prognostic nutritional index predicts nintedanib outcomes in idiopathic pulmonary fibrosis
Therapeutic Advances in Respiratory Disease · 2026-08 · 20
DOI: 10.1177/17534666261478394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 12.08.2026. Verfasst von Eri Hayakawa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-Ku, Japan. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Indoles, Nutritional Status, Nutrition Assessment. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Malnutrition is common in patients with idiopathic pulmonary fibrosis (IPF), and potentially affects the tolerability of antifibrotic therapy and survival. The prognostic nutritional index (PNI) is a validated prognostic marker in various diseases; however, its role in antifibrotic therapy remains unclear.
Objectives
To investigate associations between the PNI and adverse effects associated with nintedanib, treatment discontinuation, and survival in patients with IPF.
Design
Multicenter retrospective study.
Methods
Data from 167 Japanese patients with IPF who received nintedanib therapy were retrospectively analyzed. Information on clinical characteristics, laboratory data, and adverse events was collected, and the PNI was calculated. The optimal PNI cut-off value was determined using receiver operating characteristic (ROC) curves. Risk factors for treatment discontinuation and survival were identified using Cox proportional hazards models.
Results
The median treatment duration and survival time were 18 and 55 months, respectively. The PNI was significantly higher in patients who experienced nintedanib-associated adverse effects than in those who did not. ROC curve analysis identified an optimal PNI cut-off value of 47.3. Patients with a high PNI had significantly longer treatment durations and survival than those with a low PNI. Multivariate analyses identified the PNI as the only factor independently associated with both time to nintedanib discontinuation and survival.
Conclusion
The PNI predicted treatment feasibility and survival in patients with IPF. These findings highlight the clinical utility of the PNI as a dual biomarker of nutritional status and demonstrate its potential to guide individualized treatment strategies based on nutritional status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Bunkyo-Ku, Japan.
- Department of Respiratory Medicine, Juntendo University Urayasu Hospital, Urayasu, Japan.
ORCID-Profile: Motoyasu Kato
Zitieren
APA
Hayakawa, E., Kato, M., Hirano, H., Tadokoro, C., Kohmaru, M., Akimoto, T., Soma, S., Arai, Y., Nakazawa, S., Motomura, H., Sueyasu, T., Hirakawa, H., Ochi, Y., Sumiyoshi, I., Watanabe, J., Namba, Y., Togo, S., Sasaki, S., & Takahashi, K. (2026). Prognostic nutritional index predicts nintedanib outcomes in idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261478394
Vancouver
Hayakawa E, Kato M, Hirano H, Tadokoro C, Kohmaru M, Akimoto T, et al. Prognostic nutritional index predicts nintedanib outcomes in idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261478394
BibTeX
@article{Hayakawa2026,
author = {Hayakawa, Eri and Kato, Motoyasu and Hirano, Haruhiko and Tadokoro, Chisato and Kohmaru, Makiko and Akimoto, Takashi and Soma, Soichiro and Arai, Yuta and Nakazawa, Shun and Motomura, Hiroaki and Sueyasu, Takuto and Hirakawa, Haruki and Ochi, Yusuke and Sumiyoshi, Issei and Watanabe, Junko and Namba, Yukiko and Togo, Shinsaku and Sasaki, Shinichi and Takahashi, Kazuhisa},
title = {Prognostic nutritional index predicts nintedanib outcomes in idiopathic pulmonary fibrosis},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
volume = {20},
doi = {10.1177/17534666261478394}
}
EUVIMED